Michael T Eadon1,2, Judith Maddatu1, Sharon M Moe1, Arjun D Sinha1,2, Ricardo Melo Ferreira1, Brent W Miller1, S Jawad Sher1, Jing Su3, Victoria M Pratt4, Arlene B Chapman5, Todd C Skaar1, Ranjani N Moorthi1. 1. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 2. Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana. 3. Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana. 4. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana. 5. Department of Medicine, University of Chicago, Chicago, Illinois.
Abstract
Background: Patients with CKD often have uncontrolled hypertension despite polypharmacy. Pharmacogenomic drug-gene interactions (DGIs) may affect the metabolism or efficacy of antihypertensive agents. We report changes in hypertension control after providing a panel of 11 pharmacogenomic predictors of antihypertensive response. Methods: A prospective cohort with CKD and hypertension was followed to assess feasibility of pharmacogenomic testing implementation, self-reported provider utilization, and BP control. The analysis population included 382 subjects with hypertension who were genotyped for cross-sectional assessment of DGIs, and 335 subjects followed for 1 year to assess systolic BP (SBP) and diastolic BP (DBP). Results: Most participants (58%) with uncontrolled hypertension had a DGI reducing the efficacy of one or more antihypertensive agents. Subjects with a DGI had 1.85-fold (95% CI, 1.2- to 2.8-fold) higher odds of uncontrolled hypertension, as compared with those without a DGI, adjusted for race, health system (safety-net hospital versus other locations), and advanced CKD (eGFR <30 ml/min). CYP2C9-reduced metabolism genotypes were associated with losartan response and uncontrolled hypertension (odds ratio [OR], 5.2; 95% CI, 1.9 to 14.7). CYP2D6-intermediate or -poor metabolizers had less frequent uncontrolled hypertension compared with normal metabolizers taking metoprolol or carvedilol (OR, 0.55; 95% CI, 0.3 to 0.95). In 335 subjects completing 1-year follow-up, SBP (-4.0 mm Hg; 95% CI, 1.6 to 6.5 mm Hg) and DBP (-3.3 mm Hg; 95% CI, 2.0 to 4.6 mm Hg) were improved. No significant difference in SBP or DBP change were found between individuals with and without a DGI. Conclusions: There is a potential role for the addition of pharmacogenomic testing to optimize antihypertensive regimens in patients with CKD.
Background: Patients with CKD often have uncontrolled hypertension despite polypharmacy. Pharmacogenomic drug-gene interactions (DGIs) may affect the metabolism or efficacy of antihypertensive agents. We report changes in hypertension control after providing a panel of 11 pharmacogenomic predictors of antihypertensive response. Methods: A prospective cohort with CKD and hypertension was followed to assess feasibility of pharmacogenomic testing implementation, self-reported provider utilization, and BP control. The analysis population included 382 subjects with hypertension who were genotyped for cross-sectional assessment of DGIs, and 335 subjects followed for 1 year to assess systolic BP (SBP) and diastolic BP (DBP). Results: Most participants (58%) with uncontrolled hypertension had a DGI reducing the efficacy of one or more antihypertensive agents. Subjects with a DGI had 1.85-fold (95% CI, 1.2- to 2.8-fold) higher odds of uncontrolled hypertension, as compared with those without a DGI, adjusted for race, health system (safety-net hospital versus other locations), and advanced CKD (eGFR <30 ml/min). CYP2C9-reduced metabolism genotypes were associated with losartan response and uncontrolled hypertension (odds ratio [OR], 5.2; 95% CI, 1.9 to 14.7). CYP2D6-intermediate or -poor metabolizers had less frequent uncontrolled hypertension compared with normal metabolizers taking metoprolol or carvedilol (OR, 0.55; 95% CI, 0.3 to 0.95). In 335 subjects completing 1-year follow-up, SBP (-4.0 mm Hg; 95% CI, 1.6 to 6.5 mm Hg) and DBP (-3.3 mm Hg; 95% CI, 2.0 to 4.6 mm Hg) were improved. No significant difference in SBP or DBP change were found between individuals with and without a DGI. Conclusions: There is a potential role for the addition of pharmacogenomic testing to optimize antihypertensive regimens in patients with CKD.
Authors: Paul Muntner; Amanda Anderson; Jeanne Charleston; Zhen Chen; Virginia Ford; Gail Makos; Andrew O'Connor; Kalyani Perumal; Mahboob Rahman; Susan Steigerwalt; Valerie Teal; Raymond Townsend; Matthew Weir; Jackson T Wright Journal: Am J Kidney Dis Date: 2009-12-05 Impact factor: 8.860
Authors: Alexander G Vandell; Maximilian T Lobmeyer; Brian E Gawronski; Taimour Y Langaee; Yan Gong; John G Gums; Amber L Beitelshees; Stephen T Turner; Arlene B Chapman; Rhonda M Cooper-DeHoff; Kent R Bailey; Eric Boerwinkle; Carl J Pepine; Stephen B Liggett; Julie A Johnson Journal: Hypertension Date: 2012-09-04 Impact factor: 10.190
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: J D Duarte; S T Turner; B Tran; A B Chapman; K R Bailey; Y Gong; J G Gums; T Y Langaee; A L Beitelshees; R M Cooper-Dehoff; E Boerwinkle; J A Johnson Journal: Pharmacogenomics J Date: 2012-02-21 Impact factor: 3.550
Authors: A N Do; A I Lynch; S A Claas; E Boerwinkle; B R Davis; C E Ford; J H Eckfeldt; H K Tiwari; D K Arnett; M R Irvin Journal: J Hum Hypertens Date: 2016-01-21 Impact factor: 3.012
Authors: Joanna Q Hudson; Rebecca Maxson; Erin F Barreto; Katherine Cho; Amanda J Condon; Elizabeth Goswami; Jean Moon; Bruce A Mueller; Thomas D Nolin; Heather Nyman; A Mary Vilay; Calvin J Meaney Journal: Kidney Med Date: 2022-06-25